# US 6,924,137 B2 · Method for virus propagation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,924,137 B2 - Document ID: US6924137B2 - Status: Granted - Kind: B2 - Application number: 10/483,707 - Filed: 2002-07-02 - Published: 2004-11-25 - Granted: 2005-08-02 - Earliest claimed: 2001-07-18 - Assignees: Bavarian Nordic A/S - Inventors: Paul Howley; Karl Heller; Ingmar Räthe - Web page: https://patentgrep.com/patent/US6924137B2 ## CPC - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61P 31/12: Antivirals - A61P 39/00: General protective or antinoxious agents - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C12N 2710/24051: Methods of production or purification of viral material - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to a process for producing poxvirus, in particular Chordopoxvirus, wherein the poxvirus is cultivated at a temperature below 37° C. The process leads to increased virus propagation at the decreased temperature. ## Claims ### Claim 1 A process of amplifying a Chordopoxvirus characterized in that the virus is propagated in culture media at a cultivation temperature below 37° C., wherein the chordopoxvirus is selected from Avipoxvirus and modified vaccinia virus Ankara (MVA). ### Claim 2 (depends on 1) Process according to claim 1, wherein the poxvirus is propagated in chicken embryo fibroblast cells. ### Claim 3 (depends on 1) Process according to claim 1, wherein the Chordopoxvirus is propagated at a cultivation temperature of about 26° C. to about 36° C. ### Claim 4 Process of amplifying a Chordopoxvirus characterized in that the virus is propagated in chicken embryo fibroblasts at a cultivation temperature of 26° C. to 32° C. ### Claim 5 (depends on 4) Process according to claim 4, wherein the Chordopoxvirus is selected from the group consisting of Avipoxvirus and Orthopoxvirus. ### Claim 6 (depends on 5) Process according to claim 5, wherein the Orthopoxvirus is a vaccinia virus. ### Claim 7 (depends on 6) Process according to claim 6, wherein the vaccinia virus is selected from strain Elstree and modified vaccinia virus Ankara (MVA). ### Claim 8 (depends on 1) Process according to claim 1, wherein the Chordopoxvirus is propagated at a cultivation temperature of about 26° C. to 35° C. ### Claim 9 (depends on 1) Process according to claim 1, wherein the Chordopoxvirus is propagated at a cultivation temperature of about 30° C. ### Claim 10 (depends on 1) Process according to claim 1, wherein the virus propagation is performed for at least 24 hours. ### Claim 11 (depends on 1) Process according to claim 1, wherein the virus cultivation is performed for at least 2 to 3 days. ### Claim 12 (depends on 1) Process according to claim 1, wherein the Chordopoxvirus is a virus useful as a vaccine. ### Claim 13 (depends on 1) Process according to claim 1, wherein the process is performed in a stationary flask. ### Claim 14 (depends on 1) Process according to claim 1, wherein the pox virus is not a temperature sensitive mutant virus. ### Claim 15 (depends on 1) Process according to claim 1, wherein the pox-virus is not a temperature attenuated virus. ### Claim 16 (depends on 1) Process according to claim 1, wherein no lipids or surfactants are added to the culture media. ### Claim 17 (depends on 1) Process according to claim 1 wherein the modified vaccinia virus Ankara (MVA) is MVA-BN as deposited at ECACC under No. V00083008 or a derivative virus which shows the same temperature dependency as the deposited strain. ### Claim 18 (depends on 1) Process according to claim 1 wherein the Chordopoxvirus is propagated in avian cell culture. ### Claim 19 (depends on 7) Process according to claim 7 wherein the modified vaccinia virus Ankara (MVA) is MVA-BN as deposited at ECACC under No. V00083008 or a derivative virus which shows the same temperature dependency as the deposited strain. ### Claim 20 (depends on 6) Process according to claim 6 wherein the vaccinia virus is strain Elstree. ### Claim 21 (depends on 4) Process according to claim 4, wherein the Chordopoxvirus is propagated at a cultivation temperature of about 30° C. ### Claim 22 (depends on 4) Process according to claim 4, wherein the virus propagation is performed for at least 24 hours. ### Claim 23 (depends on 4) Process according to claim 4, wherein the virus cultivation is performed for at least 2 to 3 days. ### Claim 24 (depends on 4) Process according to claim 4, wherein the Chordopoxvirus is a virus useful as a vaccine. ### Claim 25 (depends on 4) Process according to claim 4, wherein the process is performed in a stationary flask. ### Claim 26 (depends on 4) Process according to claim 4, wherein the pox virus temperature sensitive mutant virus. ### Claim 27 (depends on 4) Process according to claim 4, wherein the pox-virus is not a temperature attenuated virus. ### Claim 28 (depends on 4) Process according to claim 4, wherein no lipids or surfactants are added to the culture media.